The big packages of the 1990s are long gone. Mergers mean stiffer competition for fewer positions.
Can MCOs cope with conflicting demands for cost shifting, comprehensive care, and new services for an extremely influential demographic?
HMOs are not rushing to follow the lead of the largest not-for-profit health plan because they fail to see how this makes them more competitive.
A federal court of appeals says that some benefit denials are really medical treatment decisions. Medical directors, take heed.
Federal law restricts the leverage given to negotiators for physician associations. Plans should know what is, and what is not, legal.
The impact of this debilitating disease has been largely underestimated, yet new biologic agents offer significant clinical benefit to those afflicted.
Legislation & Regulation
Several attorneys general have joined the U.S. Justice Department in questioning some AWP billing and reimbursement practices in Medicaid and Medicare.
If a doc is compensated when he schedules a patient visit to convey the routine results of a lipid test, but not when he phones the patient, which behavior will he choose?
The Formulary Files
It is expected that by 2004, 197 biologic medications will be available. Just what kind of an impact will they have on managed care?